youtube_live
Q3 2026 earnings • released • EPS beat +27,23% • Revenue beat +128,58%
See resultschevron_right
EDIT:NASDAQ
Editas Medicine Inc
2,14 US$
arrow_downward
-10,08%(-0,24) 1D
2,14 US$
0,00% (0,00)
todayPre-market
Closed: 12 ნოე, 16:00:01 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
2,33 US$
High
2,33 US$
Low
2,12 US$
Mkt. cap
330,29 მლნ.
Avg. vol.
2,35 მლნ.
Volume
883,00
52-wk high
3,94 US$
52-wk low
1,66 US$
EPS
-0,62 US$
Beta
2,09
Shares outstanding
154,34 მლნ.
No. of employees
87
Open
2,33 US$
High
2,33 US$
Low
2,12 US$
Mkt. cap
330,29 მლნ.
Avg. vol.
2,35 მლნ.
Volume
883,00
52-wk high
3,94 US$
52-wk low
1,66 US$
EPS
-0,62 US$
Beta
2,09
Shares outstanding
154,34 მლნ.
No. of employees
87
News stories
From web sources and news partners
Zacks
·
20 საათის წინ
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc